Description
Dihexa (PNB-0408) is a synthetic oligopeptide derived from angiotensin IV, studied as a potent activator of the hepatocyte growth factor / c-Met receptor signaling system. The compound binds HGF with sub-nanomolar affinity (Kd ≈ 65 pM) and is investigated as a synaptogenic research molecule with notable properties unusual for a peptide: oral bioavailability and blood-brain barrier permeability. Dihexa has been studied in preclinical models of cognitive function, Alzheimer’s disease, and dendritic spine formation, where it has been reported to promote functional synaptogenesis with high potency in neurotrophic assays. Its small molecular weight (~505 Da) and lipophilic character make it well-suited for intranasal delivery, supporting rapid absorption through the nasal mucosa and direct access to the central nervous system.
Product Highlights
• Each vial contains 10 mL solution (~100 sprays)
• Each spray delivers 0.1 mL = 400 mcg Dihexa
• Total Dihexa Content: 40 mg per vial
• Specialized pharmaceutical-grade nasal solution — designed for comfort and ease on the nose
• Unlike many other nasal sprays, this formula avoids irritation and dryness
• Packaged in Class A, lead-free pharmaceutical glass bottles
• Tamper/Child-Proof Cap + Orifice Reducer for integrity, sterility, and ease of use
Description
Dihexa is explored for selective HGF / c-Met receptor pathway activation and synaptic spine formation, with research interest in cognitive function, dendritic plasticity, neurotrophic signaling, and age-related cognitive decline models.
Benefits
• HGF / c-Met activation — studied as a high-affinity potentiator of hepatocyte growth factor signaling (Kd ≈ 65 pM)
• Synaptogenesis — investigated for functional dendritic spine formation and synaptic connectivity
• Cognitive research — explored in rodent models of Alzheimer’s-like cognitive impairment
• Blood-brain barrier permeability — examined for direct CNS access uncommon among peptide-class compounds
• Neurotrophic signaling — linked to high-potency neuronal growth assays
• Angiotensin IV pathway research — investigated as a structurally optimized angiotensin IV analog
Localized Effects with Nasal Spray
• Rapid uptake through the nasal mucosa
• Direct olfactory and trigeminal nerve pathway access to the central nervous system
• Bypasses first-pass hepatic metabolism that limits oral peptide bioavailability
• Dihexa’s small size (504.66 Da) supports efficient nasal mucosal absorption
• Particularly relevant for Dihexa given its central c-Met / synaptogenic targets in brain tissue
• Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness
What Researchers Use It For
• HGF / c-Met receptor pharmacology and signal transduction studies
• Dendritic spine formation and synaptic plasticity research
• Long-term potentiation (LTP) and hippocampal slice electrophysiology
• Cognitive performance endpoints in aged and AD-model rodents
• Comparative neurotrophic activity studies (vs BDNF, NGF, angiotensin IV)
• Angiotensin AT4 receptor / IRAP pathway investigations
Identity & Specs
• Compound: Dihexa
• Synonyms: PNB-0408; N-Hexanoyl-Tyr-Ile-(6)-aminohexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH₂
• Class: Angiotensin IV analog; HGF / c-Met activator; synaptogenic oligopeptide
• Sequence: Hexanoyl-Tyr-Ile-Ahx-NH₂
• Formula / M.W.: C₂₇H₄₄N₄O₅, ~504.66 g/mol
• CAS: 1401708-83-5
• Form: Sterile nasal spray solution
• Net per vial: 10 mL (~100 sprays)
• Total Content: 40 mg Dihexa per vial
• Concentration: 4 mg/mL (400 mcg per 0.1 mL spray)
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: Refrigerate 2–8 °C, protect from light
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
